Hikal Limited (HIKAL.NS)
INR 401.45
(1.1%)
INR 401.45
(1.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.99 Billion INR | 3.79% |
| 2022 | 12.52 Billion INR | 9.33% |
| 2021 | 11.45 Billion INR | 16.87% |
| 2020 | 9.79 Billion INR | 2.98% |
| 2019 | 9.51 Billion INR | 2.39% |
| 2018 | 9.29 Billion INR | 6.53% |
| 2017 | 8.72 Billion INR | 12.63% |
| 2016 | 7.74 Billion INR | 8.89% |
| 2015 | 7.11 Billion INR | -6.36% |
| 2014 | 7.59 Billion INR | -0.71% |
| 2013 | 7.64 Billion INR | 3.26% |
| 2012 | 7.4 Billion INR | 5.66% |
| 2011 | 7.01 Billion INR | 5.63% |
| 2010 | 6.63 Billion INR | -0.24% |
| 2009 | 6.65 Billion INR | -9.2% |
| 2008 | 7.32 Billion INR | 23.36% |
| 2007 | 5.93 Billion INR | 43.51% |
| 2006 | 4.13 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 12.45 Billion INR | 0.0% |
| 2023 Q4 | 12.99 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 12.99 Billion INR | 3.79% |
| 2022 Q4 | 12.52 Billion INR | 0.0% |
| 2022 FY | 12.52 Billion INR | 9.33% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 11.45 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 11.45 Billion INR | 16.87% |
| 2021 Q2 | 10.53 Billion INR | 0.0% |
| 2021 Q4 | 11.45 Billion INR | 0.0% |
| 2020 Q2 | 9.53 Billion INR | 0.0% |
| 2020 FY | 9.79 Billion INR | 2.98% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 9.79 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 9.51 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 8.98 Billion INR | 0.0% |
| 2019 FY | 9.51 Billion INR | 2.39% |
| 2018 FY | 9.29 Billion INR | 6.53% |
| 2018 Q4 | 9.29 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 8.72 Billion INR | 12.63% |
| 2016 FY | 7.74 Billion INR | 8.89% |
| 2015 FY | 7.11 Billion INR | -6.36% |
| 2014 FY | 7.59 Billion INR | -0.71% |
| 2013 Q4 | 7.64 Billion INR | 0.0% |
| 2013 FY | 7.64 Billion INR | 3.26% |
| 2012 Q4 | 7.4 Billion INR | 0.0% |
| 2012 FY | 7.4 Billion INR | 5.66% |
| 2012 Q2 | 14.34 Billion INR | 0.0% |
| 2011 FY | 7.01 Billion INR | 5.63% |
| 2010 FY | 6.63 Billion INR | -0.24% |
| 2009 FY | 6.65 Billion INR | -9.2% |
| 2008 FY | 7.32 Billion INR | 23.36% |
| 2007 FY | 5.93 Billion INR | 43.51% |
| 2006 FY | 4.13 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -413.376% |
| Ind-Swift Limited | 13.45 Billion INR | 3.405% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -166.964% |
| Sakar Healthcare Limited | 1.26 Billion INR | -928.663% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 91.462% |
| Innova Captab Limited | 4.89 Billion INR | -165.209% |
| Divi's Laboratories Limited | 18.99 Billion INR | 31.57% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -254.944% |
| Morepen Laboratories Limited | 4.45 Billion INR | -191.379% |
| Mankind Pharma Limited | 23.87 Billion INR | 45.57% |
| Sequent Scientific Limited | 8.27 Billion INR | -57.052% |
| Wanbury Limited | 3.15 Billion INR | -311.815% |
| Laurus Labs Limited | 42.71 Billion INR | 69.577% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -15.839% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -150.823% |
| Alembic Limited | 1.43 Billion INR | -807.402% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 20.148% |
| Neuland Laboratories Limited | 5.49 Billion INR | -136.333% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -21.357% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 80.042% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -105.326% |
| Themis Medicare Limited | 1.88 Billion INR | -588.468% |
| RPG Life Sciences Limited | 1.38 Billion INR | -841.523% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 81.899% |
| Lupin Limited | 96.23 Billion INR | 86.497% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1557.885% |
| Wockhardt Limited | 39.87 Billion INR | 67.407% |
| Vaishali Pharma Limited | 371.16 Million INR | -3401.13% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -57.501% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -4278.926% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 78.792% |
| FDC Limited | 3.7 Billion INR | -250.342% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 87.852% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1918.208% |
| Eris Lifesciences Limited | 38.26 Billion INR | 66.042% |
| Venus Remedies Limited | 1.39 Billion INR | -833.005% |
| ZIM Laboratories Limited | 2.08 Billion INR | -524.526% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -516.208% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -8032.435% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -270.69% |
| Shilpa Medicare Limited | 12.93 Billion INR | -0.483% |
| Albert David Limited | 1.15 Billion INR | -1029.888% |
| Ajanta Pharma Limited | 10.71 Billion INR | -21.331% |
| Hester Biosciences Limited | 3.59 Billion INR | -261.5% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -538.812% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 7.784% |
| Gufic Biosciences Limited | 5.59 Billion INR | -132.06% |
| Windlas Biotech Limited | 1.76 Billion INR | -637.216% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -407.375% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -654.558% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -557.533% |
| Granules India Limited | 22.95 Billion INR | 43.388% |
| Aarti Drugs Limited | 11.5 Billion INR | -12.96% |
| Bal Pharma Limited | 2.51 Billion INR | -417.462% |
| Alkem Laboratories Limited | 48.6 Billion INR | 73.264% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 92.921% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -1109.34% |
| Medicamen Biotech Limited | 940.36 Million INR | -1281.897% |
| Unichem Laboratories Limited | 8.06 Billion INR | -61.042% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -1892.23% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -4399.635% |
| Valiant Laboratories Limited | 1.05 Billion INR | -1127.948% |
| Orchid Pharma Limited | 3.84 Billion INR | -238.05% |
| Medico Remedies Limited | 438.24 Million INR | -2865.22% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -467.596% |
| Ipca Laboratories Limited | 33.74 Billion INR | 61.488% |
| Brooks Laboratories Limited | 248.6 Million INR | -5127.211% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1015.24% |
| Piramal Enterprises Limited | 560.47 Billion INR | 97.681% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 84.162% |
| NATCO Pharma Limited | 10.53 Billion INR | -23.385% |
| Suven Life Sciences Limited | 148.62 Million INR | -8643.65% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -336.963% |
| Strides Pharma Science Limited | 37.68 Billion INR | 65.513% |
| Indoco Remedies Limited | 10.34 Billion INR | -25.648% |
| Alpa Laboratories Limited | 307.12 Million INR | -4131.185% |
| Lasa Supergenerics Limited | 541.92 Million INR | -2297.915% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -233.81% |